Highmark to Cover XDx's AlloMap Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – XDx today said that Highmark, a health insurer that covers around 4.8 million lives in Pennsylvania and West Virginia, is now covering its AlloMap test for beneficiaries of the health plan.

The AlloMap test is a gene expression-based assay used to aid the monitoring of heart transplant rejection. The test measures the expression levels of 20 genes from a blood sample to provide a score that is used by clinicians to help evaluate the risk of transplant rejection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.